Rigel Pharmaceuticals (RIGL) Net Margin (2010 - 2026)

Rigel Pharmaceuticals' Net Margin history runs 16 years deep, the most recent figure standing at 14.71% for Q1 2026.

• In Q1 2026, Net Margin fell 675.0% year-over-year to 14.71%; the TTM figure through Mar 2026 stood at 121.51% (up 10320.0% YoY), while the FY2025 annual figure was 124.72%, up 11497.0% from the prior year.
• Net Margin for Q1 2026 stood at 14.71%, down from 384.04% in the prior quarter.
• The five-year high for Net Margin was 384.04% in Q4 2025, with the low at 164.0% in Q1 2022.
• The 5-year median for Net Margin is 0.17% (2023), against an average of 8.67%.
• The sharpest annual moves came in 2022 and 2025: Net Margin slumped 21275 bps in 2022, then jumped 35914 bps in 2025.
• Rigel Pharmaceuticals' Net Margin stood at 2.73% in 2022, then plunged by 106 bps to 0.17% in 2023, then surged by 14710 bps to 24.9% in 2024, then surged by 1442 bps to 384.04% in 2025, then tumbled by 96 bps to 14.71% in 2026.
• Business Quant data shows RIGL's Net Margin at 14.71% in Q1 2026, 384.04% in Q4 2025, and 40.17% in Q3 2025.